IHCP *banner page*

INDIANA HEALTH COVERAGE PROGRAMS BR201439 SEPTEMBER 30, 2014

DEA to reschedule hydrocodone-containing drug products as Schedule II drugs

The Drug Enforcement Agency (DEA) finalized a ruling August 22, 2014, to reschedule hydrocodone and combination hydrocodone-containing products as Schedule II drugs. The final rule will go into effect October 6, 2014. At that time, all United States-marketed pharmaceuticals containing hydrocodone will be subject to Schedule II requirements, including but not limited to requirements related to DEA registration, security protocols, labeling and packaging, inventory, and recordkeeping and reporting.

No prescription for hydrocodone-containing products issued on or after October 6, 2014, will authorize any refills. Prescriptions for hydrocodone-containing products issued before October 6, 2014, and authorized for refilling may be dispensed, if such dispensing occurs before April 8, 2015.

For more information, see the DEA Rule at deadiversion.usdoj.gov.

Current Indiana Health Coverage Programs pharmacy prior authorizations (PAs) and claims processing for hydrocodone-containing products will be unaffected by this change. Please direct questions about this article to the Catamaran Clinical and Technical Help Desk by calling toll-free 1-855-577-6317.

The IHCP clarifies process for submitting pharmacy prior authorizations

The Indiana Health Coverage Programs (IHCP) reminds providers that per Indiana Administrative Code (*405 IAC 5-3-2* and *405 IAC 5-3-10*), a prior authorization (PA) request must be submitted by the prescribing provider. Prescribers must submit PA requests to the IHCP pharmacy benefit manager, Catamaran, using one of the following methods:

- Telephone: 1-855-577-6317
- Email: Member.ServicesINM@sxc.com
- Fax: 1-855-577-6384

To avoid delays in processing PA requests, prescribing providers should:

- Use current versions of PA request forms, available online under the Pharmacy Services quick link at indianamedicaid.com.
- Complete PA request forms in their entirety and submit forms with all required attachments.

continue

In some circumstances, pharmacy providers may intervene to preclude PA requirements identified by system edits. Table 1 lists the circumstances when a pharmacist's intervention may eliminate the need for PA.

Table 1 – Accepted pharmacist interventions that may preclude a PA requirement

PA Edits	Pharmacist Intervention
Level 1 drug/drug interaction	If the prescriber had previously directed the pharmacist to discontinue one of the drugs involved in the Level 1 drug/drug interaction, the pharmacist may provide this information to Catamaran, eliminating the interaction concern and allowing the other drug claim to be approved.
Early refill	The long-term care (LTC) facility's pharmacy may inform Catamaran that the member has been admitted to the LTC facility, allowing the early refill to be approved.
Atypical antipsychotic 15-day limit	If the pharmacist is made aware the member has used the drug on at least a trial basis through samples or a previous non-IHCP prescription, the 15-day trial limit may be precluded.
High dollar limit	If the edit was due to a claim entry error, the pharmacist may reverse the claim, correct the entry, and resubmit the claim.

Please direct questions about this article to the Catamaran Clinical and Technical Help Desk by calling toll-free 1-855-577-6317.

SIGN UP FOR IHCP EMAIL NOTIFICATIONS



To receive email notices of IHCP publications, subscribe by clicking the blue subscription envelope here or on the pages of indianamedicaid.com.

COPIES OF THIS PUBLICATION

If you need additional copies of this publication, please download them from indianamedicaid.com.

TO PRINT

A printer-friendly version of this publication, in black and white and without graphics, is available for your convenience.